［1］SIEGEL RL,MILLER KD,JEMAL A. Cancer statistics,2017［J］.CA Cancer J Clin,2017,67(1):7-30.
［2］XIAO M,YANG S,CHEN J,et al.Overexpression of MMSET in endometrial cancer:a clinicopathologic study［J］.Journal of surgical oncology,2013,107(4):428-432.
［3］AYTES A,GIACOBBE A,MITROFANOVA A,et al.NSD2 is a conserved driver of metastatic prostate cancer progression［J］.Nature communications,2018,9(1):5201.
［4］MORISHITA M.Cancers and the NSD family of histone lysine methyltransferases［J］.Biochimica et Biophysica Acta,2011,1816(2):158-163.
［5］LI Y,TROJER P,XU CF,et al.The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate［J］.The Journal of Biological Chemistry,2009,284(49):34283-34295.
［6］JENUWEIN T.Translating the histone code［J］.Science(New York,N.Y.),2001,293(5532):1074-1080.
［7］CHITALE S.DICER- and MMSET-catalyzed H4K20me2 recruits the nucleotide excision repair factor XPA to DNA damage sites［J］.The Journal of Cell Biology,2018,217(2):527-540.
［8］WEI S,LI C,YIN Z,et al.Histone methylation in DNA repair and clinical practice:new findings during the past 5-years［J］.Journal of Cancer,2018,9(12):2072-2081.
［9］PEI H,ZHANG L,LUO K,et al.MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites［J］.Nature,2011,470(7332):124-128.
［10］HAJDU I,CICCIA A,LEWIS SM.Wolf-Hirschhorn syndrome candidate 1 is involved in the cellular response to DNA damage［J］.Proceedings of the National Academy of Sciences of the United States of America,2011,108(32):13130-13134.
［11］SHAH MY,MARTINEZ-GARCIA E,PHILLIP JM,et al.MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents［J］.Oncogene,2016,35(45):5905-5915.
［12］XIE Z.MMSET:role and therapeutic opportunities in multiple myeloma［J］.BioMed Research International,2014,2014:636514.
［13］HUDLEBUSCH HR,SANTONI-RUGIU E,SIMON R,et al.The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors［J］.Clinical Cancer Research:an Official Journal of the American Association for Cancer Research,2011,17(9):2919-2933.
［14］PING YANG,LINLANG GUO,ZHIJIAN J,et al.Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation,survival,and tumor growth via a feed-forward loop［J］.Mol Cell Biol,2012,32(15):3121-3131.
［15］GARCíA-CARPIZO V,SARMENTERO J,HAN B,et al.NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation［J］.Scientific Reports,2016,6:32952.
［16］HE C,LIU C,WANG L,et al.Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma［J］.Cell Death & Disease,2019,10(2):65.
［17］SWAROOP A,OYER JA,WILL CM,et al.An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia［J］.Oncogene,2019,38(5):671-686.
［18］LI N,XUE W,YUAN H,et al.AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis［J］.The Journal of Clinical Investigation,2017,127(4):1284-1302.
［19］EZPONDA T,POPOVIC R,SHAH MY,et al.The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer［J］. Oncogene,2013,32(23):2882-2890.
［20］WAN X,LIU J,LU JF,et al.Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells［J］.Clinical Cancer Research:an Official Journal of the American Association for Cancer Research,2012,18(3):726-736.
［21］TOYOKAWA G,CHO HS,MASUDA K,et al.Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway［J］.Neoplasia (New York,NY),2011,13(10):887-898.
［22］YANG YA.EZH2,an epigenetic driver of prostate cancer［J］.Protein & Cell,2013,4(5):331-341.
［23］MELLING N,THOMSEN E,TSOURLAKIS MC,et al.Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters［J］.Carcinogenesis,2015,36(11):1333-1340.
［24］ASANGANI IA,ATEEQ B,CAO Q,et al.Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer［J］.Molecular cell,2013,49(1):80-93.
［25］HADDADI N,LIN Y,TRAVIS G,et al.PTEN/PTENP1:'Regulating the regulator of RTK-dependent PI3K/Akt signalling',new targets for cancer therapy［J］.Molecular Cancer,2018,17(1):37.
［26］MCLOUGHLIN NM,MUELLER C,GROSSMANN TN.The therapeutic potential of PTEN modulation:Targeting strategies from gene to protein［J］.Cell Chem Biol,2018,25(1):19-29.
［27］YANG J,MANI SA,DONAHER JL,et al.Twist,a master regulator of morphogenesis,plays an essential role in tumor metastasis［J］.Cell,2004,117(7):927-939.
［28］RUGGERO K,FARRAN-MATAS S,MARTINEZ-TEBAR A.Epigenetic regulation in prostate cancer progression［J］.Current Molecular Biology Reports,2018,4(2):101-115.
［29］马鸿翔.多西他赛联合泼尼松化疗方案对转移性去势抵抗性前列腺癌的效果［J］.临床医药文献电子杂志,2019,6(14):37.
MA HX.Effect of docetaxel combined with prednisone on metastatic castration-resistant prostate cancer［J］.Journal of Clinical Medical Literature,2019,6(14):37.